All Stories

  1. Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: communication from the SSC of the ISTH
  2. International opinion survey on nomenclature for platelet-type von Willebrand disease: communication from the SSC of the ISTH
  3. Early vs Delayed Bypass Surgery in Patients With Acute Coronary Syndrome Receiving Ticagrelor
  4. Can the Present Canadian Health Care System Provide Evidence-Based Pharmaceutical Care? Consideration of Two Important Cardiovascular Clinical Contexts
  5. Factor XIII-A Transglutaminase Contributes to Neutrophil Extracellular Trap (NET)-mediated Fibrin(ogen) Network Formation and Crosslinking
  6. Prospective, international, multisite comparison of platelet isolation techniques for genome-wide transcriptomics: communication from the SSC of the ISTH
  7. Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH
  8. Effect of Heat Exposure on Inflammation and Platelet Activity in Adults with Heart Disease
  9. The intriguing role of platelets as custodians of brain-derived neurotrophic factor
  10. Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy
  11. Association of laboratory test results with the bleeding history in patients with inherited platelet function disorders (the Bleeding Assesment Tool - LABoratory tests substudy): communication from the Platelet Physiology ISTH-SSC
  12. Megakaryocytes possess a STING pathway that is transferred to platelets to potentiate activation
  13. Alpha-2-macroglobulin prevents platelet aggregation induced by brain-derived neurotrophic factor
  14. Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology
  15. Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH
  16. Soluble p75 neurotrophic receptor as a reliable biomarker in neurodegenerative diseases: what is the evidence?
  17. Consensus report on flow cytometry for platelet function testing in thrombocytopenic patients: communication from the SSC of the ISTH
  18. Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress
  19. Assessment of Platelet Function by High-Throughput Screening Light Transmission Aggregometry: Optimul Assay
  20. Plasminogen Activator Inhibitor-1–Positive Platelet-Derived Extracellular Vesicles Predicts MACE and the Proinflammatory SMC Phenotype
  21. Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  22. Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
  23. Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
  24. Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities
  25. Clinical Correlates Identify ProBDNF and Thrombo-Inflammatory Markers as Key Predictors of Circulating p75NTR Extracellular Domain Levels in Older Adults
  26. Rare missense variants in Tropomyosin‐4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding
  27. Editorial: Established and Novel Roles of Platelets in Health and Disease
  28. Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
  29. A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMED-F1 study
  30. Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
  31. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  32. Differences in platelet‐rich plasma composition influence bone healing
  33. The brain-derived neurotrophic factor prompts platelet aggregation and secretion
  34. Brain-Derived Neurotrophic Factor Mitigates the Association Between Platelet Dysfunction and Cognitive Impairment
  35. Effect of Paper Versus Digital Reading in Health Professional Education: A Systematic Review and Meta-Analysis
  36. The effect of aging on the bone healing properties of blood plasma
  37. Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
  38. A randomized double-blind pilot study comparing cetirizine with diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions.
  39. The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  40. Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison
  41. Platelet Function in Viral Immunity and SARS-CoV-2 Infection
  42. Platelet Quiescence in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Bypass Graft Surgery
  43. Tissue-Specificity of Antibodies Raised Against TrkB and p75NTR Receptors; Implications for Platelets as Models of Neurodegenerative Diseases
  44. Severity of Megakaryocyte‐Driven Osteosclerosis in Mpig6b ‐Deficient Mice Is Sex‐Linked
  45. Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non‐hypertensive Alzheimer's patients
  46. Implications of the Antiplatelet Therapy Gap Left with Discontinuation of Prasugrel in Canada
  47. Platelets Selectively Regulate the Release of BDNF, But Not That of Its Precursor Protein, proBDNF
  48. Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model
  49. Advances in Platelet Function Testing—Light Transmission Aggregometry and Beyond
  50. Platelet count and disease – editorial policy
  51. Effects of reading media on reading comprehension in health professional education
  52. Differential correlation of serum BDNF and microRNA content in rats with rapid or late onset of heavy alcohol use
  53. Head-to-Head Comparison of Consensus-Recommended Platelet Function Tests to Assess P2Y12 Inhibition—Insights for Multi-Center Trials
  54. Differential Correlation of Serum BDNF and microRNA Content in Rats with Rapid or Late Onset of Heavy Alcohol Use
  55. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC
  56. A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease
  57. Platelet Function in Aging
  58. Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP study
  59. Clinical Tests of Platelet Function
  60. 750
  61. Increased platelet reactivity and platelet–leukocyte aggregation after elective coronary bypass surgery
  62. An interview with Professor Gus Born
  63. Clinical importance of thrombocytopenia in patients with acute coronary syndromes: a systematic review and meta-analysis
  64. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy
  65. Platelets at the heart of therapy
  66. Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery
  67. Personalizing antiplatelet therapies: What have we learned from recent trials?
  68. Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial
  69. Mice Lacking the Inhibitory Collagen Receptor LAIR-1 Exhibit a Mild Thrombocytosis and Hyperactive PlateletsHighlights
  70. PREVALENCE AND CLINICAL IMPACT OF THROMBOCYTOPENIA IN PATIENTS WITH ACUTE CORONARY SYNDROMES: A SYSTEMATIC REVIEW AND META-ANALYSIS
  71. Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid
  72. Platelet Function Tests
  73. Tests of Platelet Function
  74. ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON THE USE OF TICAGRELOR VERSUS CLOPIDOGREL PRIOR TO SURGERY
  75. ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON TIMING OF DISCONTINUATION OF TICAGRELOR AND CLOPIDOGREL PRIOR TO SURGERY
  76. The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
  77. Platelet function testing as a biomarker for efficacy of antiplatelet drugs
  78. Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects
  79. Platelet function tests
  80. Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation
  81. Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?
  82. SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects
  83. The role of platelets in the recruitment of leukocytes during vascular disease
  84. Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review
  85. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis
  86. The prognostic utility of tests of platelet function for the detection of ‘aspirin resistance’ in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation
  87. Use of next‐generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders
  88. Diversity and impact of rare variants in genes encoding the platelet G protein-coupled receptors
  89. Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease
  90. Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease
  91. A novel mutation in the P2Y12 receptor and a function‐reducing polymorphism in protease‐activated receptor 1 in a patient with chronic bleeding
  92. Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders
  93. Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay
  94. A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction
  95. Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects
  96. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders
  97. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists
  98. Corrigendum
  99. Genotyping and phenotyping of platelet function disorders
  100. Testing Platelet Function
  101. Simultaneous measurement of ATP release and LTA does not potentiate platelet aggregation to epinephrine
  102. Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: Identification of the second HPS7 mutation in a patient presenting late in life
  103. OC-13 Investigation of underlying platelet function defects in patients with unexplained menorrhagia
  104. Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease
  105. Clinical Tests of Platelet Function
  106. G6f-Like Is an ITAM-Containing Collagen Receptor in Thrombocytes
  107. Platelet Turnover in Atherothrombotic Disease
  108. Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel
  109. Advances in monitoring of aspirin therapy
  110. Aspirin twice a day keeps new COX-1 at bay
  111. 50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams
  112. Genetic determinants of response to aspirin: Appraisal of 4 candidate genes
  113. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease
  114. Beware of being caught on the rebound
  115. Why an aspirin a day no longer keeps the doctor away …
  116. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin
  117. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel
  118. Prevalence of Unresponsiveness to Aspirin and/or Clopidogrel in Patients With Stable Coronary Heart Disease
  119. Evaluation of the platelet count drop method for assessment of platelet function in comparison with “gold standard” light transmission aggregometry
  120. Week-Long High-Maintenance Dose Clopidogrel Regimen Achieves Better Platelet Aggregation Inhibition than a Standard Loading Dose before Percutaneous Coronary Intervention: Results of a Double-Blind, Randomized Clinical Trial
  121. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence
  122. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2
  123. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients
  124. Assessment of VerifyNow P2Y12 Assay Accuracy in Evaluating Clopidogrel-Induced Platelet Inhibition
  125. Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic: reply
  126. Normal Response to Aspirin in Healthy Individuals: Cross-Comparison of Light Transmission Aggregometry, VerifyNow™ System, Platelet Count Drop, Thrombelastography (TEG®) and Urinary 11-dehydrothromboxane B2.
  127. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
  128. Aspirin resistance: Truth or dare